Yifang Bio Stock Plunges 30%: Is the AI Drug Discovery Sector Losing Steam?
In the spring of 2026, Yifang Bio — once hailed as the 'Disneyland of Pharma' — saw its stock price plunge over 30%, tri…
4 articles about 'biopharmaceuticals'
In the spring of 2026, Yifang Bio — once hailed as the 'Disneyland of Pharma' — saw its stock price plunge over 30%, tri…
Gilead Sciences has completed its first key technical breakout in 11 years. AI-driven quantitative analysis models indic…
Liaoning Chengda Biotech has established a wholly-owned subsidiary, Shanghai Chengda Zhiyuan Pharmaceutical Technology C…
RemeGen released its Q1 2026 earnings report, posting revenue of 656 million yuan, a year-over-year increase of 24.76%, …